The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial∗
Jihad Georges Youssef, Philip Lavin, David A. Schoenfeld, Richard A. Lee, Rainer Lenhardt, David J. Park, Javier Perez Fernandez, Melvin L. Morganroth, Jonathan C. Javitt, Dushyantha Jayaweera
Dive into the research topics of 'The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial∗'. Together they form a unique fingerprint.